Boston Scientific Taxus Inventory Of 150,000 Planned For U.S. Launch

Boston Scientific projects a 60% U.S. drug-eluting stent market penetration "right out of the gate" for its soon-to-be-launched Taxus, according to Senior VP and Cardiovascular Group President Paul LaViolette